Immune effector cells toxicity management
Revision as of 13:21, 23 September 2023 by Warner-admin (talk | contribs)
| Page co-editor | Page co-editor | ||
|---|---|---|---|
 |
Leyre Zubiri, MD, PhD Massachusetts General Hospital Boston, MA |
 |
Matthew Hadfield, DO Lifespan/Brown University Providence, RI |
The purpose of this page is to address the management of toxicity from bispecific T-cell engager and immune effector cell (IEC) therapy, notably CAR-T. There is a separate page for the management of immune checkpoint inhibitor (ICI) toxicities, available here.
- We have moved How I Treat articles to a dedicated page.
Guidelines
ASCO
- 2021: Santomasso et al. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
ASTCT
- 2019: Lee et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
EBMT/JACIE/EHA
- 2022: Hayden et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) PubMed
SITC
- 2020: Maus et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events